Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Takeda Reportedly Offering $12B For Europe's Nycomed

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.

Related Content

As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts
Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop
Nycomed CEO Hakan Bjorklund On Emerging Markets As Core Focus For Growth: An Interview With PharmAsia News
Nycomed Prepares To Launch First Nonprescription PPI With EU-Wide Approval
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts